Here's What I'm Planning With My Eli Lilly Position
Summary
Parkev provides a bullish analysis of Eli Lilly, emphasizing the massive success of its weight-loss portfolio, which includes both injectable and newly developed pill versions. Parkev notes that the company's revenue has surged to nearly $80 billion, more than doubling in just a few years, while operating margins have expanded to an impressive 49.7%. Beyond weight loss, Parkev highlights the company's long-term expertise in research and development, which has yielded a return on invested capital of nearly 40%, far exceeding its costs.
Parkev acknowledges potential headwinds from government regulation regarding drug pricing but suggests that drastic measures are unlikely to halt the company's progress without stifling innovation. From a valuation perspective, Parkev finds the forward P/E ratio of 26 to be attractive given the superior growth characteristics. Parkev calculates a fair value of $1,523 per share, indicating significant upside from current levels.
Mentioned Stocks
Reasoning: Parkev highlights the booming business driven by weight-loss treatments and a massive revenue jump to $79.7 billion. He points to an exceptional return on invested capital of nearly 40% and strong operating margins of 49.7%. Parkev calculates a fair value of $1,523 per share, representing over 20% upside from the current price of $1,251, and considers the forward P/E of 26 to be an attractive entry point.